Obicetrapib
Heterozygous Familial Hypercholesterolemia (HeFH) and/or established Atherosclerotic Cardiovascular Disease (ASCVD)
Key Facts
About NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.
View full company profile